CN112839708A - 用于减少或治疗纤维化的组合物和方法 - Google Patents

用于减少或治疗纤维化的组合物和方法 Download PDF

Info

Publication number
CN112839708A
CN112839708A CN201980054596.4A CN201980054596A CN112839708A CN 112839708 A CN112839708 A CN 112839708A CN 201980054596 A CN201980054596 A CN 201980054596A CN 112839708 A CN112839708 A CN 112839708A
Authority
CN
China
Prior art keywords
amino acid
composition
acid entity
entity
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054596.4A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈米尔
瑞弗·亚非恩
李中伟
哈利·路易特哈特
卢克·S·哈姆
斯维特拉娜·马鲁基安
纳丁·道尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of CN112839708A publication Critical patent/CN112839708A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980054596.4A 2018-06-20 2019-06-19 用于减少或治疗纤维化的组合物和方法 Pending CN112839708A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862687718P 2018-06-20 2018-06-20
US62/687,718 2018-06-20
US201862758174P 2018-11-09 2018-11-09
US62/758,174 2018-11-09
US201962794154P 2019-01-18 2019-01-18
US62/794,154 2019-01-18
PCT/US2019/038036 WO2019246298A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the reduction or treatment of fibrosis

Publications (1)

Publication Number Publication Date
CN112839708A true CN112839708A (zh) 2021-05-25

Family

ID=67253997

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054596.4A Pending CN112839708A (zh) 2018-06-20 2019-06-19 用于减少或治疗纤维化的组合物和方法

Country Status (6)

Country Link
US (1) US20210275480A1 (https=)
EP (1) EP3810272A1 (https=)
JP (1) JP2021527669A (https=)
CN (1) CN112839708A (https=)
MA (1) MA52960A (https=)
WO (1) WO2019246298A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
WO2023009444A1 (en) * 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038289A2 (en) * 2007-09-17 2009-03-26 Seoul National University Industry Foundation Pharmaceutical compositions for preventing or treating fibrosis
CA2873745A1 (en) * 2012-05-16 2013-11-21 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
WO2015061607A1 (en) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038289A2 (en) * 2007-09-17 2009-03-26 Seoul National University Industry Foundation Pharmaceutical compositions for preventing or treating fibrosis
CA2873745A1 (en) * 2012-05-16 2013-11-21 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
WO2015061607A1 (en) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. GRASEMANN等: "A randomized controlled trial of inhaled L-Arginine in patients with cystic fibrosis", JOURNAL OF CYSTIC FIBROSIS, vol. 12, no. 5, pages 468 - 474, XP055239423, DOI: 10.1016/j.jcf.2012.12.008 *

Also Published As

Publication number Publication date
EP3810272A1 (en) 2021-04-28
US20210275480A1 (en) 2021-09-09
WO2019246298A1 (en) 2019-12-26
JP2021527669A (ja) 2021-10-14
MA52960A (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
CN110087647B (zh) 氨基酸组合物及肝疾病的治疗方法
JP2021119180A (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
CN107206021A (zh) 使用降氨疗法治疗与肝星状细胞激活相关的疾病
CN112839712A (zh) 用于减少或治疗发炎的组合物和方法
CN112839708A (zh) 用于减少或治疗纤维化的组合物和方法
TW201836669A (zh) 抑制肌纖維變性用組成物
JPWO2017010537A1 (ja) 環状ジペプチド含有血清カルノシン分解酵素阻害用組成物
CN105435230B (zh) O-GlcNAc糖基化修饰在防治肝纤维化中的应用
Zhou et al. Cathelicidin-BF regulates the AMPK/SIRT1/NF-κB pathway to ameliorate murine osteoarthritis: in vitro and in vivo studie
US20240252588A1 (en) Composition for preventing or treating vascular diseases, containing hapln1
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用
JPWO2007060924A1 (ja) 膵β細胞保護剤
US20130059913A1 (en) Composition for amelioration of hypoalbuminemia
KR102089376B1 (ko) 디아민 유도체를 포함하는 뇌졸중, 신경 세포 손상, 파킨슨병 또는 루게릭병의 예방 또는 치료용 조성물
CN118593506A (zh) 一种化合物a或其衍生物在制备预防和治疗肝纤维化疾病的药物中的应用
OA19827A (en) Amino acid compositions and methods for the treatment of liver diseases.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525

WD01 Invention patent application deemed withdrawn after publication